Eagle Pharmaceuticals, Inc. 1E6.F Stock
Eagle Pharmaceuticals, Inc. Price Chart
Eagle Pharmaceuticals, Inc. 1E6.F Financial and Trading Overview
Eagle Pharmaceuticals, Inc. stock price | 4.08 EUR |
Previous Close | 16.3 EUR |
Open | 17.2 EUR |
Bid | 17.2 EUR x 20000 |
Ask | 17.4 EUR x 20000 |
Day's Range | 17.2 - 17.2 EUR |
52 Week Range | 16.9 - 46 EUR |
Volume | 1 EUR |
Avg. Volume | 3 EUR |
Market Cap | 225.17M EUR |
Beta (5Y Monthly) | 0.89683 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0.86 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 48.5 EUR |
1E6.F Valuation Measures
Enterprise Value | 282.25M EUR |
Trailing P/E | N/A |
Forward P/E | 3.0442479 |
PEG Ratio (5 yr expected) | 6.46 |
Price/Sales (ttm) | 0.8432053 |
Price/Book (mrq) | 0.9267242 |
Enterprise Value/Revenue | 1.057 |
Enterprise Value/EBITDA | 4.086 |
Trading Information
Eagle Pharmaceuticals, Inc. Stock Price History
Beta (5Y Monthly) | 0.89683 |
52-Week Change | -57.21% |
S&P500 52-Week Change | 20.43% |
52 Week High | 46 EUR |
52 Week Low | 16.9 EUR |
50-Day Moving Average | 22.92 EUR |
200-Day Moving Average | 28.03 EUR |
1E6.F Share Statistics
Avg. Volume (3 month) | 3 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 13.09M |
Float | 11.53M |
Short Ratio | N/A |
% Held by Insiders | 13.09% |
% Held by Institutions | 89.56% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -0.99% |
Operating Margin (ttm) | 19.62% |
Gross Margin | 68.36% |
EBITDA Margin | 25.86% |
Management Effectiveness
Return on Assets (ttm) | 8.91% |
Return on Equity (ttm) | -1.16% |
Income Statement
Revenue (ttm) | 267.04M EUR |
Revenue Per Share (ttm) | 20.51 EUR |
Quarterly Revenue Growth (yoy) | -42.79% |
Gross Profit (ttm) | 221.67M EUR |
EBITDA | 69.08M EUR |
Net Income Avi to Common (ttm) | -2666000 EUR |
Diluted EPS (ttm) | -0.24 |
Quarterly Earnings Growth (yoy) | -86.90% |
Balance Sheet
Total Cash (mrq) | 21.9M EUR |
Total Cash Per Share (mrq) | 1.67 EUR |
Total Debt (mrq) | 78.97M EUR |
Total Debt/Equity (mrq) | 32.52 EUR |
Current Ratio (mrq) | 1.968 |
Book Value Per Share (mrq) | 18.56 |
Cash Flow Statement
Operating Cash Flow (ttm) | 33.8M EUR |
Levered Free Cash Flow (ttm) | 76.85M EUR |
Profile of Eagle Pharmaceuticals, Inc.
Country | Germany |
State | NJ |
City | Woodcliff Lake |
Address | 50 Tice Boulevard |
ZIP | 07677 |
Phone | 201 326 5300 |
Website | https://www.eagleus.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 134 |
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Q&A For Eagle Pharmaceuticals, Inc. Stock
What is a current 1E6.F stock price?
Eagle Pharmaceuticals, Inc. 1E6.F stock price today per share is 4.08 EUR.
How to purchase Eagle Pharmaceuticals, Inc. stock?
You can buy 1E6.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Eagle Pharmaceuticals, Inc.?
The stock symbol or ticker of Eagle Pharmaceuticals, Inc. is 1E6.F.
Which industry does the Eagle Pharmaceuticals, Inc. company belong to?
The Eagle Pharmaceuticals, Inc. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Eagle Pharmaceuticals, Inc. have in circulation?
The max supply of Eagle Pharmaceuticals, Inc. shares is 13.55M.
What is Eagle Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Eagle Pharmaceuticals, Inc. PE Ratio is 4.74418600 now.
What was Eagle Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Eagle Pharmaceuticals, Inc. EPS is 0.86 EUR over the trailing 12 months.
Which sector does the Eagle Pharmaceuticals, Inc. company belong to?
The Eagle Pharmaceuticals, Inc. sector is Healthcare.